Thomas Salentine, Jr. Sells 3,570,677 Shares of Guardian Pharmacy Services (NYSE:GRDN) Stock

Guardian Pharmacy Services, Inc. (NYSE:GRDN) Director Thomas Salentine, Jr. sold 3,570,677 shares of the business’s stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $29.68, for a total transaction of $105,977,693.36. Following the completion of the sale, the director owned 4,469,316 shares in the company, valued at approximately $132,649,298.88. This trade represents a 44.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Guardian Pharmacy Services Trading Down 3.0%

Shares of NYSE:GRDN opened at $35.41 on Friday. The company has a market cap of $2.24 billion, a price-to-earnings ratio of 45.98 and a beta of 0.86. Guardian Pharmacy Services, Inc. has a 12 month low of $19.17 and a 12 month high of $38.12. The company has a 50-day moving average price of $32.74 and a 200 day moving average price of $29.91.

Guardian Pharmacy Services (NYSE:GRDN) last issued its quarterly earnings data on Wednesday, March 11th. The company reported $0.37 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.10. Guardian Pharmacy Services had a return on equity of 31.64% and a net margin of 3.40%.The company had revenue of $397.62 million for the quarter, compared to analysts’ expectations of $390.04 million. The firm’s revenue was up 17.4% compared to the same quarter last year. As a group, equities analysts forecast that Guardian Pharmacy Services, Inc. will post 0.87 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Truist Financial increased their price target on Guardian Pharmacy Services from $34.00 to $38.00 and gave the company a “buy” rating in a report on Thursday, March 12th. Oppenheimer lifted their price objective on shares of Guardian Pharmacy Services from $35.00 to $38.00 and gave the stock an “outperform” rating in a research note on Thursday, March 12th. UBS Group reiterated a “buy” rating on shares of Guardian Pharmacy Services in a research report on Thursday, March 12th. Zacks Research raised shares of Guardian Pharmacy Services from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 18th. Finally, Stephens raised their target price on shares of Guardian Pharmacy Services from $35.00 to $36.00 and gave the stock an “overweight” rating in a report on Wednesday, January 14th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $38.00.

Institutional Investors Weigh In On Guardian Pharmacy Services

Institutional investors and hedge funds have recently modified their holdings of the business. State of Alaska Department of Revenue purchased a new position in Guardian Pharmacy Services during the 3rd quarter valued at $30,000. Ameritas Investment Partners Inc. increased its stake in Guardian Pharmacy Services by 26.5% in the third quarter. Ameritas Investment Partners Inc. now owns 1,647 shares of the company’s stock worth $43,000 after purchasing an additional 345 shares during the period. Raymond James Financial Inc. purchased a new stake in Guardian Pharmacy Services in the second quarter worth $43,000. Police & Firemen s Retirement System of New Jersey lifted its position in shares of Guardian Pharmacy Services by 76.8% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 2,444 shares of the company’s stock worth $52,000 after purchasing an additional 1,062 shares during the last quarter. Finally, State of Wyoming bought a new stake in shares of Guardian Pharmacy Services during the second quarter worth $58,000.

Trending Headlines about Guardian Pharmacy Services

Here are the key news stories impacting Guardian Pharmacy Services this week:

• Positive Sentiment: Q3 / latest quarter: GRDN beat EPS and revenue estimates (revenue +17.4% YoY), which supports growth expectations. MarketBeat GRDN summary
• Positive Sentiment: Analyst momentum: several firms (Truist, Raymond James, Oppenheimer, Stephens, Zacks) have raised targets or ratings recently, leaving a buy/strong-buy consensus and a ~$38 average target. Analyst coverage
• Neutral Sentiment: Institutional holders: several funds (Vanguard, Wellington, Brown Advisory, Franklin, Valiant) have recently adjusted positions; this shows continuing institutional interest but mixed flows. Holders data
• Neutral Sentiment: Market writeups flagged “major insider exodus,” useful for context but not new filings by itself. TipRanks article
• Negative Sentiment: Director Thomas J. Salentine, Jr. sold 3,570,677 shares at ~$29.68 (~$106.0M), a ~44% reduction — a large block that likely pressured the stock. SEC filing
• Negative Sentiment: Director William E. Bindley sold 3,570,677 shares at ~$29.68 (~$106.0M), a ~44% reduction — another very large director sale. SEC filing
• Negative Sentiment: Director John Ackerman sold 1,103,364 shares at ~$29.68 (~$32.7M), a ~76% reduction in his stake. SEC filing
• Negative Sentiment: Officer Fred Burke sold 671,432 shares at ~$29.68 (~$19.9M), a ~44% cut to his position. SEC filing
• Negative Sentiment: Insider Kendall Forbes sold 346,672 shares at ~$29.68 (~$10.3M), reducing her holding by ~43%. SEC filing
• Negative Sentiment: Insider David K. Morris sold 187,855 shares at ~$29.68 (~$5.6M), cutting his position by ~42%. SEC filing
• Negative Sentiment: Major shareholder Equity Fund L.P. (Cardinal) sold 275,728 shares at ~$29.68 (~$8.2M), a ~44% stake reduction — signals significant institutional unloading. SEC filing

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.